The differential diagnostic potential of a panel of tumor markers (CA 125, CA 15-3, and CA 72-4 antigens) in patients with a pelvic mass

Schutter, Eltjo M.J.; Davelaar, Elvira M.; Kamp, Gerard J. van; Verstraeten, Rob A.; Kenemans, P.; Verheijen, René H.M.

doi:10.1067/mob.2002.123768

Cited by 36 publications

(30 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, the flexibility of Lab-MAP technology allows for the addition of new markers and therefore for the opportunity to incrementally increase the diagnostic power of the combined assay. To the best of our knowledge, the reported multiplexed cytokines/CA-125 offers the highest predictive power, as compared with other published assays using defined protein serologic markers (3,14,30,(32)(33)(34)(35)(36)(37)(38)(39)(59)(60)(61)(62).…”

Section: Discussionmentioning

confidence: 86%

“…In some studies, combinations of several markers have been evaluated for early detection of ovarian cancer using conventional ELISA assays. Analysis of the diagnostic power of individual serologic markers in combination with CA-125 resulted in increased sensitivity and specificity (3,14,(30)(31)(32)(33)(34)(35)(36)(37)(38)(39). Due to the limitations of ELISA (which is expensive, timeconsuming, and each assay encompasses only one marker at a time), none of the tested marker combinations thus far was sufficiently comprehensive and achieved the required characteristics for diagnosis of ovarian cancer.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Multiplexed Immunobead-Based Cytokine Profiling for Early Detection of Ovarian Cancer

Gorelik

Landsittel

Marrangoni

et al. 2005

Cancer Epidemiology, Biomarkers &Amp; Prevention

244

164

View full text Add to dashboard Cite

Early detection of ovarian cancer might improve clinical outcome. Some studies have shown the role of cytokines as a new group of tumor markers for ovarian cancer. We hypothesized that a panel comprised of multiple cytokines, which individually may not show strong correlation with the disease, might provide higher diagnostic power. To evaluate the diagnostic utility of cytokine panel, we used a novel multianalyte LabMAP profiling technology that allows simultaneous measurement of multiple markers. Concentrations of 24 cytokines (cytokines/chemokines, growth, and angiogenic factors) in combination with cancer antigen-125 (CA-125), were measured in sera of 44 patients with earlystage ovarian cancer, 45 healthy women, and 37 patients with benign pelvic tumors. Six markers, i.e., interleukin (IL)-6, IL-8, epidermal growth factor (EGF), vascular endothelial growth factor (VEGF), monocyte chemoattractant protein-1 (MCP-1), and CA-125, showed significant differences in serum concentrations between ovarian cancer and control groups. Out of this group, IL-6, IL-8, VEGF, EGF, and CA-125, were used in a classification tree analysis that resulted in 84% sensitivity at 95% specificity. The receiver operator characteristic curve created using the combination of markers produced sensitivities between 90% and 100% in the area of 80% to 90% specificity, whereas the receiver operator characteristic curve for CA-125 alone resulted in sensitivities of 70% to 80%. The classification tree analysis for discrimination of benign condition from ovarian cancer used CA-125, granulocyte colony-stimulating factor (G-CSF), IL-6, EGF, and VEGF resulting in 86.5% sensitivity and 93.0% specificity. The presented data show that simultaneous testing of a panel of serum cytokines and CA-125 using LabMAP technology may present a promising approach for ovarian cancer detection.

show abstract

Section: Discussionmentioning

confidence: 86%

Section: Introductionmentioning

confidence: 99%

Multiplexed Immunobead-Based Cytokine Profiling for Early Detection of Ovarian Cancer

Gorelik

Landsittel

Marrangoni

et al. 2005

Cancer Epidemiology, Biomarkers &Amp; Prevention

244

164

View full text Add to dashboard Cite

show abstract

“…Preoperative CA-125 can be used to predict severe endometriosis and malignant disease of the ovary (33,34). In general, the sensitivity of CA-125 in predicting ovarian cancer is 81% to 91% (35)(36)(37)(38). We assumed a higher incidence of elevated serum CA-125 in patients with EEOC because a significant number of patients displayed comorbidity with endometriosis.…”

Section: Discussionmentioning

confidence: 99%

Clinical Presentation of Endometrioid Epithelial Ovarian Cancer with Concurrent Endometriosis: A Multicenter Retrospective Study

Lim

Chun

Shin

et al. 2010

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

Background: Endometrioid epithelial ovarian cancer (EEOC) is frequently diagnosed in conjunction with endometriosis and is suggested to arise during the process of endometriosis. This study evaluates the clinical manifestations, including endometriosis-related symptoms and their relationships according to the coexistence of endometriosis.Methods: Using medical records, a retrospective analysis was conducted on 221 patients treated for EEOC at four tertiary educational hospitals between 2000 and 2008. The initial presenting symptoms, particularly those related to endometriosis, were examined in relation to the coexistence of endometriosis or other clinical variables.Results: Endometriosis was identified in 82 (37.1%) of the 221 patients with EEOC. The most common symptoms were pelvic pain followed by gastrointestinal symptoms, palpable mass, abdominal distension, vaginal bleeding, and newly developed or exacerbated dysmenorrhea (18.1%) and dyspareunia (13.6%). Notably, dysmenorrhea and dyspareunia were frequently observed in patients with endometriosis. Among 210 patients identified with pretreatment serum CA-125, 54 (25.7%) displayed normal CA-125 levels (<35 units/ mL) and 23.3% and 29.9% of patients without and with endometriosis had normal CA-125 levels, respectively (P = 0.381). Additionally, 32.6% of the patients with early-stage EEOC displayed normal CA-125 levels.Conclusions: In this large series of patients with EEOC, the main presenting symptoms were pelvic pain followed by gastrointestinal symptoms, palpable mass, abdominal distension, vaginal bleeding, and newly developed or exacerbated dysmenorrhea and dyspareunia. Dyspareunia and dysmenorrhea were more frequently detected in patients with endometriosis. Normal CA-125 levels cannot be applied as a marker to exclude EEOC, particularly at the early stages. Cancer Epidemiol Biomarkers Prev; 19(2); 398-

show abstract

“…11 Stakes et al found CA 125 to be 86% for risk of ovarian cancer algorithm and specificity of 98% for CA 125 component of algorithm.…”

Section: Discussionmentioning

confidence: 99%

Combined use of CA 125 and Inhibin as tumor marker for detection of ovarian cancer in comparison to CA 125 or Inhibin alone

Dubbewar¹,

Pathak²,

Biswas³

et al. 2017

Int J Reprod Contracept Obstet Gynecol

View full text Add to dashboard Cite

Background: Ovarian cancers are diagnosed at an advanced stage. Early diagnosis is the key to reduce death from ovarian cancer. The present study is an effort to assess the suitability of combined test using CA 125 and Inhibin for early diagnosis of ovarian cancer as compared to CA125 or Inhibin alone.Methods: Fifty women with clinical suspicion of ovarian malignancy attending Gynae OPD were enrolled. All of these women were subjected to estimation of CA 125 and Inhibin levels prior to surgical intervention. A value of 35 IU/ml was taken as positive for CA 125. For Inhibin, 10.5 pg/ml was taken as cut off for premenopausal patients, whereas, any detectable assays were taken as positive for postmenopausal patients. The results were analyzed after establishing final histopathology of the disease.Results: Out of 50 patients recruited, 30 (60%) were found to have carcinoma ovary and 20 (40%) were found to have benign diseases. Out of 30 cases of carcinoma ovary, CA125 was raised in 81% of cases and Inhibin was raised in 78% of cases. For detection of carcinoma ovary, CA 125 was found to have a sensitivity of 90% and specificity of 60% with a positive predictive value of 77% and negative predictive value of 80% which were statistically significant. Sensitivity and specificity of serum Inhibin for the same was 86.6% and 20% respectively. The positive and negative predictive value were 61.9% and 50%, which were not statistically significant. Sensitivity and specificity of combined CA125 and Inhibin were 100% and 30% respectively. The positive and negative predictive value were 68.1% and 100% respectively, which were statistically significant.Conclusions: Combined use of CA125 and Inhibin has got better sensitivity and specificity in detection of ovarian cancer in comparison to CA 125 or Inhibin used alone.

show abstract

The differential diagnostic potential of a panel of tumor markers (CA 125, CA 15-3, and CA 72-4 antigens) in patients with a pelvic mass

Cited by 36 publications

References 19 publications

Multiplexed Immunobead-Based Cytokine Profiling for Early Detection of Ovarian Cancer

Multiplexed Immunobead-Based Cytokine Profiling for Early Detection of Ovarian Cancer

Clinical Presentation of Endometrioid Epithelial Ovarian Cancer with Concurrent Endometriosis: A Multicenter Retrospective Study

Combined use of CA 125 and Inhibin as tumor marker for detection of ovarian cancer in comparison to CA 125 or Inhibin alone

Contact Info

Product

Resources

About